Structure Therapeutics (GPCR) Liabilities and Shareholders Equity (2022 - 2026)

Structure Therapeutics' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 74.04% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $4.7 billion (up 29.88% YoY), while the FY2025 annual figure was $1.6 billion, up 75.34% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.5 billion, down from $1.6 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.6 billion in Q4 2025, with the low at $97.8 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $824.3 million (2025), against an average of $722.9 million.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity surged 392.63% in 2023, then fell 13.79% in 2025.
• Structure Therapeutics' Liabilities and Shareholders Equity stood at $97.8 million in 2022, then soared by 392.63% to $482.0 million in 2023, then soared by 87.41% to $903.3 million in 2024, then surged by 75.34% to $1.6 billion in 2025, then slipped by 4.79% to $1.5 billion in 2026.
• Business Quant data shows GPCR's Liabilities and Shareholders Equity at $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $832.2 million in Q3 2025.